

ForPatients

by Roche

Colorectal Cancer (CRC)

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Trial Status
Terminated

Trial Runs In
5 Countries

Trial Identifier
NCT03555149 2017-004566-99
CO39612

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT03555149 2017-004566-99 CO39612
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years

Healthy Volunteers
No
